GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 16, 877–897 (2017).

Article  Google Scholar 

Dorsey, E. R., Sherer, T., Okun, M. S. & Bloem, B. R. The emerging evidence of the Parkinson pandemic. J. Parkinsons Dis. 8, S3–S8 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Uebelacker, L. A., Epstein-Lubow, G., Lewis, T., Broughton, M. K. & Friedman, J. H. A survey of Parkinson’s disease patients: most bothersome symptoms and coping preferences. J. Parkinsons Dis. 4, 717–723 (2014).

Article  PubMed  Google Scholar 

Antonini, A., Emmi, A. & Campagnolo, M. Beyond the dopaminergic system: lessons learned from levodopa resistant symptoms in Parkinson’s disease. Mov. Disord. Clin. Pract. 10, S50–S55 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Vijayakumar, D. & Jankovic, J. Drug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesia. Drugs 76, 759–777 (2016).

Article  CAS  PubMed  Google Scholar 

Aquino, C. C. & Fox, S. H. Clinical spectrum of levodopa-induced complications. Mov. Disord. 30, 80–89 (2015).

Article  CAS  PubMed  Google Scholar 

Antonini, A., Moro, E., Godeiro, C. & Reichmann, H. Medical and surgical management of advanced Parkinson’s disease. Mov. Disord. 33, 900–908 (2018).

Article  PubMed  Google Scholar 

Ayers, J. I. et al. Different α-synuclein prion strains cause dementia with Lewy bodies and multiple system atrophy. Proc. Natl Acad. Sci. USA 119, e2113489119 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

So, R. W. L. & Watts, J. C. α-Synuclein conformational strains as drivers of phenotypic heterogeneity in neurodegenerative diseases. J. Mol. Biol. 435, 168011 (2023).

Article  CAS  PubMed  Google Scholar 

Calabresi, P. et al. Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 14, 176 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Pringsheim, T. et al. Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary. Neurology 97, 942–957 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Stathis, P., Konitsiotis, S. & Antonini, A. Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias. Expert Rev. Neurother. 15, 207–213 (2015).

Article  CAS  PubMed  Google Scholar 

Clarke, C. et al. 15-Year effects of initiating treatment for Parkinson’s disease with dopamine agonists or monoamine oxidase B inhibitors compared with levodopa: final results of PD MED early disease randomisation [abstract]. Mov. Disord. 38 (Suppl. 1), Abstract 41 (2023).

Google Scholar 

Olanow, C. W., Poewe, W., Rascol, O. & Stocchi, F. On-demand therapy for OFF episodes in Parkinson’s disease. Mov. Disord. 36, 2244–2253 (2021).

Article  PubMed  Google Scholar 

Olanow, C. W., Obeso, J. A. & Stocchi, F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol. 5, 677–687 (2006).

Article  CAS  PubMed  Google Scholar 

Antonini, A. et al. Comparative effectiveness of device-aided therapies on quality of life and off-time in advanced Parkinson’s disease: a systematic review and Bayesian network meta-analysis. CNS Drugs 36, 1269–1283 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Demailly, A., Moreau, C. & Devos, D. Effectiveness of continuous dopaminergic therapies in Parkinson’s disease: a review of L-DOPA pharmacokinetics/pharmacodynamics. J. Parkinsons Dis. 14, 925–939 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leta, V. et al. Gastrointestinal barriers to levodopa transport and absorption in Parkinson’s disease. Eur. J. Neurol. 30, 1465–1480 (2023).

Article  PubMed  Google Scholar 

Stocchi, F., Jenner, P. & Obeso, J. A. When do levodopa motor fluctuations first appear in Parkinson’s disease? Eur. Neurol. 63, 257–266 (2010).

Article  CAS  PubMed  Google Scholar 

Cenci, M. A. Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications. Front. Neurol. 5, 242 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Calabresi, P., Filippo, M. D., Ghiglieri, V., Tambasco, N. & Picconi, B. Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to-bedside gap. Lancet Neurol. 9, 1106–1117 (2010).

Article  CAS  PubMed  Google Scholar 

Abbruzzese, G., Barone, P., Lopiano, L. & Stocchi, F. The current evidence for the use of safinamide for the treatment of Parkinson’s disease. Drug Des. Devel. Ther. 15, 2507–2517 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Ferreira, J. J. et al. Effect of opicapone on levodopa pharmacokinetics in patients with fluctuating Parkinson’s disease. Mov. Disord. 37, 2272–2283 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rocha, J. F. et al. The safety/tolerability of opicapone when used early in Parkinson’s disease patients with levodopa-induced motor fluctuations: a post-hoc analysis of BIPARK-I and II. Front. Neurol. 13, 994114 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Schuepbach, W. M. M. et al. Neurostimulation for Parkinson’s disease with early motor complications. N. Engl. J. Med. 368, 610–622 (2013).

Article  CAS  PubMed  Google Scholar 

Ko, T. H. et al. Magnetic resonance-guided focused ultrasound surgery for Parkinson’s disease: a mini-review and comparison between deep brain stimulation. Parkinsonism Relat. Disord. 111, 105431 (2023).

Article  PubMed  Google Scholar 

Coelho, M. & Ferreira, J. In: Movement Disorders Curricula (eds Falup-Pecurariu, C., Ferreira, J., Martinez-Martin, P. & Chaudhuri, K. R.) 129–137 (Springer, 2017).

Garon, M. et al. Quantification of brain β-amyloid load in Parkinson’s disease with mild cognitive impairment: a PET/MRI study. Front. Neurol. 12, 760518 (2022).

Article  PubMed  PubMed Central  Google Scholar 

McFarthing, K. et al. Parkinson’s disease drug therapies in the clinical trial pipeline: 2023 update. J. Parkinsons Dis. 13, 427–439 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hauser, R. A. et al. IPX203 vs immediate-release carbidopa-levodopa for the treatment of motor fluctuations in Parkinson disease: the RISE-PD randomized clinical trial. JAMA Neurol. 80, 1062–1069 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Soileau, M. J. et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 21, 1099–1109 (2022).

Article  CAS  PubMed  Google Scholar 

Espay, A. J. et al. Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson’s disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial. Lancet Neurol. 23, 465–476 (2024).

Article  CAS  PubMed  Google Scholar 

Olanow, C. W. et al. Continuous versus intermittent oral administration of levodopa in Parkinson’s disease patients with motor fluctuations: a pharmacokinetics, safety, and efficacy study. Mov. Disord. 34, 425–429 (2019).

Article